Form 4: Centessa Pharmaceuticals Executive Tia L. Bush Reports Share Transactions

Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, reports the acquisition and disposal of ordinary shares, including shares withheld for tax obligations and sales under a Rule 10b5-1 trading plan.

Summary

• Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals plc, filed a Form 4 detailing changes in beneficial ownership.
• On February 1, 2025, 8,693 ordinary shares were withheld by the issuer at a price of $16.92 to cover tax obligations related to vesting restricted share units.
• On February 3, 2025, Bush sold 11,000 ordinary shares at a weighted average price of $16.8551.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024.
• Bush also acquired options to purchase 125,000 ordinary shares at an exercise price of $16.90, vesting monthly starting March 3, 2025, and expiring on February 3, 2035.
• Following these transactions, Bush directly owns 121,503 ordinary shares and options for 125,000 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing share transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of share options demonstrates continued alignment of the executive's interests with the company's long-term performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the share options.

Industry Context

Form 4 filings are standard practice for reporting insider transactions in publicly traded companies, providing transparency to investors.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the pharmaceutical industry to incentivize performance and align executive interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price of the options are typical for such arrangements.

Stakeholder Impact

• Shareholders are informed about executive share transactions, contributing to transparency.
• Employees may be indirectly affected by the perceived alignment of executive interests with company performance.

Key Dates

Keywords

Form 4, Centessa Pharmaceuticals, CNTA, Tia L. Bush, Beneficial Ownership, Share Transactions, Rule 10b5-1, Stock Options, Executive Compensation